Teleflex (TFX) AI Stock Analysis

• Market Cap: $5.41B
• Dividend Yield: 1.11%
• Average Volume (3M): 495.35K
• Price to Earnings (P/E): 38.6
• Beta (1Y): 0.77
• Revenue Growth: 0.29%
• EPS Growth: -48.98%
• Country: US
• Employees: 14,100
• Sector: Healthcare
• Sector Strength: 55
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 2.91
• Shares Outstanding: 44,188,984
• 10 Day Avg. Volume: 483,317
• 30 Day Avg. Volume: 495,351
• PEG Ratio: -1.27
• Price to Book (P/B): 2.91
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 44.52
• Enterprise Value/Market Cap: 2.45
• Enterprise Value/Revenue: 1.10
• Enterprise Value/Gross Profit: 7.90
• Enterprise Value/Ebitda: 5.99
• 1Y Price Target: $143.40
• Price Target Upside: 17.44% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 8

• Rating: 58 Neutral
• Price Target: ―

Teleflex's solid financial performance is offset by technical indicators pointing towards bearish sentiment and perceived overvaluation. Strategic initiatives and acquisitions offer potential long-term growth, but near-term challenges such as revenue declines and operational pressures weigh down the outlook.

Positive Factors

Mergers and Acquisitions

TFX has started to engage potential buyers for NewCo, and the interest in acquiring NewCo is described as significant, validating the separated businesses as good assets.

Product Portfolio

TFX’s branded product portfolio will become much larger with the Biotronik acquisition, providing growth opportunities.

Negative Factors

Financial Guidance

Management lowered GM and OM guidance for the year.

Tariffs

Management characterized the current tariff impact as a 'worst case' scenario with no mitigation efforts yet in place.

Teleflex Business Overview & Revenue Model

Company Description

Teleflex Incorporated is a global provider of medical technologies designed to improve the health and quality of people's lives. The company operates in sectors including vascular access, anesthesia, cardiac care, urology, and respiratory care, among others. Teleflex's core products and services encompass a wide range of medical devices used in hospitals and healthcare facilities worldwide, including catheters, medical tubing, and surgical instruments.

How the Company Makes Money

Teleflex makes money primarily through the sale of its medical devices and technologies to hospitals, healthcare providers, and distributors. The company's revenue model is based on manufacturing and distributing a broad portfolio of products that address critical care and surgical needs across various medical specialties. Key revenue streams include sales from its vascular and interventional access products, anesthesia and respiratory care products, and surgical products. Additionally, Teleflex benefits from strategic partnerships with healthcare institutions and continuous investment in research and development, which help enhance its product offerings and maintain its competitive edge in the medical technology industry.

Teleflex Financial Statement Overview

Summary

Teleflex exhibits strong financial health with robust cash flow management and stable balance sheet metrics. Profitability is strong, though there are some operational cost challenges as reflected in the lower EBIT margin.

Income Statement

Teleflex shows strong profitability with a Gross Profit Margin of 55.7% and Net Profit Margin of 5.0% in TTM. Revenue grew modestly at 0.6% from the previous year, indicating stable growth. Notably, the EBITDA Margin stands at 15.9%, reflecting healthy operational efficiency. However, the EBIT Margin is somewhat lower at 8.6%, suggesting some operational cost challenges.

Balance Sheet

The company maintains a solid financial structure with a Debt-to-Equity Ratio of 0.05, indicating low leverage. The Return on Equity is 3.6% in TTM, which is moderate but could be improved. The Equity Ratio is robust at 57.2%, showcasing a strong equity base. Overall, the balance sheet is stable with manageable debt levels.

Cash Flow

Teleflex exhibits strong cash flow management, with a Free Cash Flow to Net Income Ratio of 3.41 in TTM, indicating efficient cash generation relative to earnings. The Operating Cash Flow to Net Income Ratio is 4.00, highlighting strong cash conversion. Free Cash Flow has grown slightly by 0.2% from the previous year, maintaining positive cash flow growth.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.01B	3.05B	2.97B	2.79B	2.81B	2.54B
	Gross Profit
1.68B	1.70B	1.65B	1.53B	1.55B	1.32B
	EBIT
290.63M	151.01M	506.31M	499.73M	628.10M	423.07M
	EBITDA
479.36M	452.66M	761.21M	751.65M	873.10M	665.98M
	Net Income Common Stockholders
149.39M	69.67M	356.33M	363.14M	485.37M	335.32M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
284.12M	290.19M	222.85M	292.03M	445.08M	375.88M
	Total Assets
7.16B	7.10B	7.53B	6.93B	6.87B	7.15B
	Total Debt
2.00B	1.76B	1.93B	1.83B	1.97B	2.56B
	Net Debt
1.72B	1.46B	1.70B	1.54B	1.52B	2.19B
	Total Liabilities
3.07B	2.82B	3.09B	2.91B	3.12B	3.82B
	Stockholders Equity
4.10B	4.28B	4.44B	4.02B	3.75B	3.34B
Cash Flow		Free Cash Flow
479.84M	509.31M	419.20M	262.95M	579.80M	345.71M
	Operating Cash Flow
597.85M	635.74M	510.64M	342.14M	651.42M	436.41M
	Investing Cash Flow
-103.34M	-99.36M	-621.23M	-257.94M	156.74M	-837.78M
	Financing Cash Flow
-350.48M	-421.93M	38.54M	-217.51M	-715.82M	455.16M

Teleflex Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 122.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TFX, the sentiment is Negative. The current price of 122.1 is below the 20-day moving average (MA) of 123.23, below the 50-day MA of 127.22, and below the 200-day MA of 176.52, indicating a bearish trend. The MACD of -1.43 indicates Negative momentum. The RSI at 44.49 is Neutral, neither overbought nor oversold. The STOCH value of 56.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TFX.

Teleflex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	76 Outperform	$5.62B	46.30	9.16%	―	8.24%	18.54%
HAE	76 Outperform	$3.47B	21.56	18.83%	―	3.95%	44.09%
ICUI	68 Neutral	$3.31B	―	-4.62%	―	7.19%	-56.19%
TFX	58 Neutral	$5.41B	38.60	3.48%	1.11%	0.29%	-48.98%
BLCO	57 Neutral	$4.45B	―	-5.56%	―	11.94%	-6.98%
RGEN	56 Neutral	$7.42B	―	-1.16%	―	4.88%	-196.93%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%

Teleflex Corporate Events

Teleflex Amends Bylaws to Ease Stockholder Actions

On May 9, 2025, Teleflex Incorporated’s Board of Directors approved amendments to the company’s bylaws, specifically removing a section that required stockholder actions to occur only at official meetings. This change could impact how stockholder decisions are made in the future. Additionally, during the 2025 annual meeting, stockholders voted on various proposals, including the election of directors and executive compensation, with most proposals receiving majority approval, except for a stockholder proposal on special meeting requirements.

The most recent analyst rating on (TFX) stock is a Buy with a $285.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.

Teleflex Raises Revenue Outlook Amid Q1 Revenue Decline

Teleflex reported a decrease in first-quarter revenues for 2025, with a 5.0% decline compared to the previous year, and adjusted diluted EPS also fell from $3.21 to $2.91. Despite these challenges, the company raised its full-year revenue growth outlook on a GAAP basis and completed a $300 million accelerated share repurchase. Teleflex is also exploring the separation into two independent companies, which has attracted significant third-party interest. The company is working on strategies to mitigate the impact of tariffs, which are expected to cost approximately $55 million in 2025.